Walmsley – the first woman to run a major pharma firm – overhauled the Brentford based drugmaker narrowing priorities for drug development and setting a target of allocating 80 per cent of pharma research and development capital to a maximum of four disease areas.
She’ll be replaced by chief commercial officer Luke Miels.
Shares in GSK closed up 2.6 per cent on the news to 1,536.50.
